Live In Play

Live In Play®

Updated: 14-May-26 15:24 ET

STAA: STAAR Surgical +8.4% nicely higher following Q1 results, China saw launch of key product, early demand has been good (31.93 +2.53)

STAAR Surgical (STAA) is the star of the show after this supplier of implantable lenses reported Q1 results.
What is interesting is that STAA guided last month to Q1 revenue being "in excess of $90 mln" which it was at $93.5 mln. The odd thing is that analysts seem to have not updated their models so this final number was well above the formal analyst expectation. But the Q1 revenue was not really new information.
We suspect that investors were also pleased with the Q1 EPS upside as STAA did not guide for EPS last month, so that was new.
There were other positives as well. STAA said that the launch of EVO+ ICL in China represents an important step forward in its innovation strategy and that early demand has exceeded expectations. Also, while the overall US refractive surgery market has declined in recent years, STAA says its business has continued to grow through share gains as adoption of EVO ICL has increased.